Merck Advances Phase 3 ADC Study in Metastatic Colorectal Cancer

Merck announced the first patient has been dosed in the Phase 3 PROCEDE-CRC-03 study evaluating investigational antibody-drug conjugate (ADC) precemtabart tocentecan in patients with metastatic colorectal cancer whose disease has progressed after prior therapies.^1,2 The candidate targets CEACAM5, a protein frequently overexpressed in colorectal tumors and associated with tumor growth and disease progression in several gastrointestinal cancers.^1,3

The randomized global study is comparing the ADC against investigator’s choice chemotherapy in previously treated patients with metastatic disease. According to the company, the trial is intended to further evaluate efficacy and safety in a late-line colorectal cancer setting where therapeutic options remain limited and patient prognosis is often poor following progression on standard regimens.^1,2

Why are CEACAM5-targeted ADCs drawing attention?

ADCs have become one of the most closely watched modalities in oncology because they combine the precision targeting of monoclonal antibodies with the cell-killing effects of cytotoxic payloads.^3,4 By selectively delivering chemotherapy agents directly to tumor cells, ADCs are designed to improve antitumor activity while reducing systemic toxicity compared with conventional chemotherapy approaches.³

CEACAM5 has emerged as an attractive target because of its elevated expression in colorectal and other gastrointestinal tumors.³ Several companies have explored CEACAM5-directed therapies over the past decade, though relatively few programs have advanced into late-stage clinical development. Merck’s advancement into Phase 3 therefore represents a significant milestone for this class of targeted therapeutics in colorectal cancer.^1,4

Earlier clinical findings for precemtabart tocentecan showed encouraging antitumor activity and a manageable safety profile. Merck previously reported a confirmed objective response rate of 20.7% at the recommended Phase 3 dose of 2.8 mg/kg administered every three weeks.^1,2 Researchers are now looking to determine whether those findings can translate into improved progression-free survival and broader clinical benefit in a larger patient population.

How does this fit into the broader ADC development landscape?

The advancement of PROCEDE-CRC-03 reflects continued momentum in the broader oncology ADC market, which has seen rapid investment and clinical expansion in recent years.^3,4 Multiple biopharmaceutical companies are advancing late-stage ADC candidates across solid tumor indications including breast, lung, ovarian, and gastrointestinal cancers.⁴

Industry interest has accelerated as improvements in linker technology, payload engineering, and antibody specificity have increased the stability and therapeutic index of next-generation ADCs.^3,4 Several recently approved ADC therapies have demonstrated strong commercial performance and clinical activity, contributing to growing confidence in the modality across the oncology sector.

Analysts also view colorectal cancer as an important frontier for ADC development because many patients eventually develop resistance to standard chemotherapy and targeted therapies. As a result, drug developers are increasingly exploring novel mechanisms and biomarker-driven approaches to address unmet need in advanced disease settings.³

What could the study mean for patients with metastatic colorectal cancer?

Metastatic colorectal cancer remains a major global health burden and continues to be one of the leading causes of cancer-related death worldwide.³ Patients whose disease progresses after standard treatment often face limited therapeutic options and declining survival outcomes.

If successful, the Phase 3 study could help establish a new targeted treatment approach for heavily pretreated colorectal cancer patients while also validating CEACAM5-directed ADCs as a viable therapeutic strategy in gastrointestinal oncology.^1,3 Positive results could further strengthen industry momentum toward precision oncology approaches that combine biomarker targeting with advanced drug delivery technologies.

References

1. Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer. (2026 May 21). Business Wire. https://www.businesswire.com/news/home/20260521312109/en/Merck-Announces-First-Patient-Dosed-in-Phase-3-Study-for-Investigational-Antibody-Drug-Conjugate-in-Colorectal-Cancer
2. Merck KGaA Announces First Patient Dosed in Phase 3 Study. (2026 May 21). MorningStar. https://www.morningstar.com/news/business-wire/20260521854864/merck-kgaa-darmstadt-germany-announces-first-patient-dosed-in-phase-3-study-for-investigational-antibody-drug-conjugate-in-colorectal-cancer
3. Antibody-Drug Conjugates for Solid Tumors (2024 Oct). Nature. https://www.nature.com/collections/ffbceeadei
4. Coyle, L. (2026 Jan). Industry Insights: Converging modalities drive the next wave of bioconjugate therapies. Bioconjugate Insights. https://www.researchgate.net/publication/400633787_Industry_Insights_Converging_modalities_drive_the_next_wave_of_bioconjugate_therapies